Insomnia: Recent advances in pharmacological management

Drug Benefit Trends

Volumn 21, Issue 9, 2009, Pages 266-271

  Neubauer, David N ^a,b  

^a Department of Psychiatry and Behavioral Sciences ^*

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Insomnia; Sleep disorders

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ADIPIPLON; AGOMELATINE; ALMOREXANT; BDD 40001; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CASOPITANT; DIPHENHYDRAMINE; DOXEPIN; E 6199; ESTAZOLAM; ESZOPICLONE; EVT 201; FLURAZEPAM; GABOXADOL; HYPNOTIC AGENT; INDIPLON; MIRTAZAPINE; OSEMOZOTAN; PD 200390; PREGABALIN; QUAZEPAM; RAMELTEON; RO 438554; TEMAZEPAM; TIK 301; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEC 162; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

AROUSAL; DIZZINESS; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; HUMAN; INSOMNIA; LOW DRUG DOSE; NIGHT; PAIN; REVIEW; RISK REDUCTION; SEDATION; SIDE EFFECT; SLOW WAVE SLEEP; SOMNOLENCE; SUSTAINED DRUG RELEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 72149101578     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Neubauer DN. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med. 2007;3(5 suppl):S11-S15.
2. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep. 2005;28:1049-1057.
3. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487-495. (Pubitemid 41671203)
4. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double- blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26:793-799. (Pubitemid 39610622)
5. Krystal AD, Erman M, Zammit GK, et al; ZOLONG Study Group. Long-term efficacy and safety of Zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6- month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31:79-90.
6. DeMicco M, Wang-Weigand S, Zhang J. Long- term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a 1 year study. Sleep. 2006;29(suppl):A234. Abstract.
7. Zammit GK. The prevalence, morbidities, and treatments of insomnia. CNS Neurol Disord Drug Targets. 2007;6:3-16.
8. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300:2-8.
9. Greenblatt DJ. Pharmacokinetic determinants of hypnotic drug action: the art and science of controlling release. Sleep Med. 2006 May 12; [Epub ahead of print].
10. Moen MD, Plosker GL. Zolpidem extended- release. CNS Drugs. 2006;20:419-428.
11. Lankford A, Ancoli-Israel S. Indiplon: the development of a novel therapy for the treatment of sleep onset and sleep maintenance insomnia. Int J Clin Pract. 2007;61:1037-1045. (Pubitemid 46744062)
12. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301-310. (Pubitemid 40208266)
13. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63:1149-1157.
14. McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005;19:1057-1067.
15. Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opin Investig Drugs. 2007;16:1785-1797. (Pubitemid 350187392)
16. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007; 13:150-155.
17. Tashiro M, Yanai K. Molecular imaging of histamine receptors in the human brain [in Japanese]. Brain Nerve. 2007;59:221-231.
18. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30:1555-1561. (Pubitemid 350036981)
19. Walsh JK, Roehrs T, Roth T. Pharmacologic treatment of primary insomnia. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia: Elsevier Inc; 2005: 749-760.